INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
NASDAQ:IART - Nasdaq - US4579852082 - Common Stock - Currency: USD
Taking everything into account, IART scores 3 out of 10 in our fundamental rating. IART was compared to 188 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of IART while its profitability can be described as average. IART has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year IART was profitable.
In the past year IART had a positive cash flow from operations.
IART had positive earnings in 4 of the past 5 years.
IART had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of IART (-0.71%) is better than 71.81% of its industry peers.
IART has a better Return On Equity (-1.90%) than 72.34% of its industry peers.
IART has a Return On Invested Capital of 4.48%. This is in the better half of the industry: IART outperforms 76.60% of its industry peers.
IART had an Average Return On Invested Capital over the past 3 years of 6.10%. This is in line with the industry average of 7.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.71% | ||
| ROE | -1.9% | ||
| ROIC | 4.48% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
IART has a better Operating Margin (10.34%) than 77.66% of its industry peers.
IART's Operating Margin has declined in the last couple of years.
IART's Gross Margin of 58.47% is in line compared to the rest of the industry. IART outperforms 55.85% of its industry peers.
In the last couple of years the Gross Margin of IART has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.34% | ||
| PM (TTM) | N/A | ||
| GM | 58.47% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IART is still creating some value.
The number of shares outstanding for IART has been reduced compared to 1 year ago.
IART has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, IART has a worse debt to assets ratio.
2.2 Solvency
IART has an Altman-Z score of 1.14. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
IART has a Altman-Z score (1.14) which is in line with its industry peers.
IART has a Debt/Equity ratio of 0.81. This is a neutral value indicating IART is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.81, IART is not doing good in the industry: 73.94% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.14 |
ROIC/WACC0.83
WACC5.42%
2.3 Liquidity
IART has a Current Ratio of 1.21. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
IART's Current ratio of 1.21 is on the low side compared to the rest of the industry. IART is outperformed by 82.45% of its industry peers.
A Quick Ratio of 0.72 indicates that IART may have some problems paying its short term obligations.
IART has a worse Quick ratio (0.72) than 89.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.72 |
3. Growth
3.1 Past
The earnings per share for IART have decreased strongly by -16.84% in the last year.
The Earnings Per Share has been decreasing by -1.35% on average over the past years.
IART shows a small growth in Revenue. In the last year, the Revenue has grown by 6.19%.
Measured over the past years, IART shows a small growth in Revenue. The Revenue has been growing by 1.20% on average per year.
EPS 1Y (TTM)-16.84%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-25.45%
Revenue 1Y (TTM)6.19%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%3.74%
3.2 Future
The Earnings Per Share is expected to grow by 4.05% on average over the next years.
IART is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.92% yearly.
EPS Next Y-10.81%
EPS Next 2Y-1.01%
EPS Next 3Y4.05%
EPS Next 5YN/A
Revenue Next Year3.34%
Revenue Next 2Y3.88%
Revenue Next 3Y3.92%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IART is valuated cheaply with a Price/Earnings ratio of 5.23.
Based on the Price/Earnings ratio, IART is valued cheaply inside the industry as 97.87% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of IART to the average of the S&P500 Index (26.25), we can say IART is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 5.05, the valuation of IART can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IART indicates a rather cheap valuation: IART is cheaper than 97.34% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of IART to the average of the S&P500 Index (22.15), we can say IART is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.23 | ||
| Fwd PE | 5.05 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IART is valued cheaply inside the industry as 95.74% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.99 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.01%
EPS Next 3Y4.05%
5. Dividend
5.1 Amount
IART does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
12.66
-0.02 (-0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners90.57%
Inst Owner Change9.1%
Ins Owners3.04%
Ins Owner Change2.02%
Market Cap983.81M
Analysts54.44
Price Target20.55 (62.32%)
Short Float %5.75%
Short Ratio3.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.18%
Min EPS beat(2)-6.76%
Max EPS beat(2)11.12%
EPS beat(4)2
Avg EPS beat(4)1.7%
Min EPS beat(4)-6.76%
Max EPS beat(4)11.12%
EPS beat(8)3
Avg EPS beat(8)2.41%
EPS beat(12)5
Avg EPS beat(12)3.04%
EPS beat(16)8
Avg EPS beat(16)4.75%
Revenue beat(2)0
Avg Revenue beat(2)-2.05%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)-1.58%
Revenue beat(4)0
Avg Revenue beat(4)-1.38%
Min Revenue beat(4)-2.51%
Max Revenue beat(4)-0.64%
Revenue beat(8)0
Avg Revenue beat(8)-1.35%
Revenue beat(12)1
Avg Revenue beat(12)-1.19%
Revenue beat(16)3
Avg Revenue beat(16)-0.84%
PT rev (1m)-18.61%
PT rev (3m)-22.53%
EPS NQ rev (1m)-24.6%
EPS NQ rev (3m)-26.44%
EPS NY rev (1m)-9.07%
EPS NY rev (3m)-10.96%
Revenue NQ rev (1m)-5.27%
Revenue NQ rev (3m)-5.71%
Revenue NY rev (1m)-0.76%
Revenue NY rev (3m)-2.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.23 | ||
| Fwd PE | 5.05 | ||
| P/S | 0.61 | ||
| P/FCF | N/A | ||
| P/OCF | 9.61 | ||
| P/B | 0.65 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.99 |
EPS(TTM)2.42
EY19.12%
EPS(NY)2.51
Fwd EY19.81%
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)1.32
OCFY10.41%
SpS20.9
BVpS19.61
TBVpS-9.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.71% | ||
| ROE | -1.9% | ||
| ROCE | 5.36% | ||
| ROIC | 4.48% | ||
| ROICexc | 4.91% | ||
| ROICexgc | 24.71% | ||
| OM | 10.34% | ||
| PM (TTM) | N/A | ||
| GM | 58.47% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexcg growth 3Y-1.99%
ROICexcg growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 3.9 | ||
| Cap/Depr | 86.65% | ||
| Cap/Sales | 7.87% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 32.45% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 1.14 |
F-Score5
WACC5.42%
ROIC/WACC0.83
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.84%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-25.45%
EPS Next Y-10.81%
EPS Next 2Y-1.01%
EPS Next 3Y4.05%
EPS Next 5YN/A
Revenue 1Y (TTM)6.19%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%3.74%
Revenue Next Year3.34%
Revenue Next 2Y3.88%
Revenue Next 3Y3.92%
Revenue Next 5YN/A
EBIT growth 1Y-33.28%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year16.37%
EBIT Next 3Y9.92%
EBIT Next 5YN/A
FCF growth 1Y-112.75%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-58.45%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%